PaperlessPTO Directory vs Targeted Asthma Therapy

Call, text or email anyone in your PTO or parent teacher organization. The directory app is a new tool that will prove beneficial to your parent teacher group. The Paperless PTO Directory App will always be in sync with your Paperless PTO website. This means that any updates to your website directory will immediately be reflected in the app. No longer will delays or typos result in mistakes in your directory. Simply make an update on your website and it will immediately appear in the directory app. Plus you can view teacher lists, classroom lists, board member information, and the group’s calendar. Even more impressive is the 100% guaranteed delivery of your email blasts. No longer will spam filters and junk folders get in the way of receiving these email blasts. Every email blast will always make it to your directory app. Other features include adding an optional personalized security code that needs to be entered every time you open the app. Advertisers on your website will also have their ads shown on the app. This will result in a greater demand for local merchants who will want to advertise with your group. Download the Paperless PTO Directory App now!

Asthma is a complex and heterogeneous chronic disease that manifests differently across patient populations, influenced by factors such as age, ethnicity, and comorbid conditions. This program explores the underlying role of type 2 inflammation in asthma pathophysiology and highlights how biomarkers—including eosinophil counts, fractional exhaled nitric oxide (FeNO), and IgE levels—can inform a more personalized approach to treatment. Participants will examine emerging evidence supporting the use of biomarker testing to define asthma phenotypes and optimize therapeutic strategies. Building on the latest Global Initiative for Asthma (GINA 2025) recommendations, this provides guidance on assessing disease severity, evaluating comorbidities, and identifying patients most likely to benefit from biologic therapy. Clinical data and practical decision-making frameworks will be reviewed that compare anti-IgE, anti–IL-5/5R, anti–IL-4/13, and anti–TSLP biologics, emphasizing their safety, efficacy, and demonstrated benefits in reducing exacerbations and improving lung function.